MultiBiotic


Multi-Strain Probiotic


Improve gut health + Reduce IBS symptoms + Support immune health

This product is Practitioner Grade. Consult your health professional before use. Alternatively, contact Medlab practitioners for advice at clinic.medlab.co. Virtual consultations for 20 minutes can be booked free of charge.

Description


MultiBiotic is a scientifically formulated, high concentration, multi-strain probiotic to restore and maintain beneficial gut bacteria.

  • Relieves abdominal discomfort and diarrhoea
  • Relief of symptoms of medically diagnosed Irritable Bowel Syndrome (IBS)
  • Supports digestive system health
  • Supports healthy immune system function
  • Maintains skin health
  • Supports intestinal health
  • Restore and maintain gut health during and after antibiotic use

Why MultiBiotic?

Containing 7 specifically selected probiotic strains, MultiBiotic is more than just for poor diets, bloats and cramps; it can rescue an unbalanced gut due to antibiotic use and assist in managing the symptoms of Irritable Bowel Syndrome (IBS).

Directions of Use


Adult Recommended Dose: Take two (2) capsules morning and night with water before meals or as directed by your healthcare professional. Consult your health care professional for children under four (4).

Indications


  • Decrease/reduce/relieve diarrhoea in children
  • Relief of symptoms of medically diagnosed Irritable Bowel Syndrome
  • Helps reduce occurrence of symptoms of medically diagnosed Irritable Bowel Syndrome
  • Maintain/support intestinal health
  • Maintain/support digestive system health
  • Helps restore good/beneficial/friendly intestinal/gut/bowel flora
  • Decrease/reduce/relieve abdominal pain/discomfort
  • Maintain/support healthy immune system function
  • Maintain/support skin health

Warning


Always read the label. Follow the directions for use. If symptoms persist, talk to your health professional. Seek medical advice if diarrhoea persists for more than: 6 hrs (age <6 months), 12 hrs (age <3 yrs), 24 hrs (age 3-6 yrs), 48 hrs (age +6 yrs and adults).

Side Effects


Some medicines may interfere with MultiBiotic™. These include:

  • Immunosuppressant Drugs
  • Antibiotics

Ingredients


Each capsule contains


Lactobacillus rhamnosus

(Med 26)

9 billion CFU


Equiv. ascrobate acid

59.4mg


Equiv. zinc

50mg


Lactobacillus acidophilus 

(Med 27)

3.75 billion CFU


Lactobacillus plantarum

(Med 25)

1.575 billion CFU


Bifidobacterium animalis ssp. lactis

(Med 13)

3 billion CFU


Bifidobacterium breve

(Med 12)

1.75 billion CFU


Bifidobacterium bifidum

(Med 11)

500 million CFU


Streptococcus thermophilus

(Med 51)

1.5 billion CFU



* CFU: Colony Forming Units


Excipents


Colloidal anhydrous silica

(Silica )

6 mg


Magnesium stearate

(Magnesium )

4 mg


Maltodextrin

(Potato )

160 mg



Related Publications


Probiotics, prebiotics and the gastrointestinal tract in health and disease
Title Content
Location Inflammopharmacology 2014; 22(3): 135-154
Date 2014-03-16
Authors Professor Luis Vitetta , Holiie Alford , Dr. Sean Hall , Dr. Samantha Coulson
Link http://link.springer.com/article/10.1007%2Fs10787-014-0201-4
High Fat Diet, Probiotics and Non-Alcoholic Fatty Liver Disease
Gut Bacteria and Health…Probiotics and the Microbiome.
Title Content
Location National Institute of Integrative Medicine, 2nd Annual Symposium November 28-29, 2015. Melbourne, Australia.
Date 2015-11-28
Authors Professor Luis Vitetta
Link https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwij8-3M3orpAhXabSsKHQoBCBAQFjAAegQIAxAB&url=https%3A%2F%2Fwww.niim.com.au%2Fsites%2Fdefault%2Ffiles%2FNIIM-2nd-Annual-Symposium-digital.pdf&usg=AOvVaw3dp-AxlQajqMi8DmvsxE0I
The Role of Gut Microbiota in Non-Alcoholic Fatty Liver Disease: The Efficacy of a Multi-Strain Probiotic in Obese Adolescents.
Title Content
Location 3rd International Conference on the Science Nutrition in Medicine and Healthcare. May 3-5, 2013. Sydney Australia
Date 2013-05-03
Authors Professor Luis Vitetta , Dr. Samantha Coulson , Talia Palacios
Link https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=2ahUKEwj5lsDs3IzpAhWT6nMBHdXfDtIQFjABegQIAxAB&url=https%3A%2F%2Fwww.anhinternational.org%2Fevent%2F3rd-international-conference-on-the-science-of-nutrition-in-medicine-and-healthcare%2F&usg=AOvVaw1xrZQGoqty0VIKDIBtUjFL
Probiotics, the gastrointestinal tract microbiome and musculoskeletal diseases.
Title Content
Location International Probiotic Association World Congress May 9-10, 2014, Athens, Greece. Beneficial Microbes 5 (suppl 1): 23.
Date 2014-05-09
Authors Professor Luis Vitetta
Probiotics for the Gastrointestinal Tract (GIT) Microbiome: The Evidence-Based Market Leader.
Title Content
Location 4th Annual Symposium of Drug Delivery System 2014 November 18-20, 2014. Suzhou, China
Date 2014-11-18
Authors Dr. Sean Hall
Reactive oxygen species and their lifelong regulation of the metabolome.
Title Content
Location 6th World Congress on Targeting Mitochondria October 28–30, 2015. Berlin, Germany.
Date 2015-10-28
Authors Professor Luis Vitetta
Probiotics in Clinical Practice and ICU.
Title Content
Location 16th Annual Meeting: Australian College of Critical Care Nurses 2015. June 19-20, 2015. Adelaide, Australia.
Date 2015-06-19
Authors Professor Luis Vitetta , Dr. Samantha Coulson
A multi-strain probiotic preparation in a mouse model of a high fat diet / obesity induced liver steatosis,
Title Content
Location 5th Science of Nutrition in Medicine and Healthcare Conference. May 2-3, 2015. Melbourne, Australia.
Date 2015-05-02
Authors Professor Luis Vitetta
Inter–Kingdom communication: bacterial instruction of host gene expression.
Title Content
Location The 5th Annual Science of Nutrition in Medicine and Healthcare Conference. May 2-3, 2015. Melbourne, Australia.
Date 2015-05-02
Authors Dr. Samantha Coulson
Indoxyl sulphate and kidney disease: Causes, consequences and interventions
Title Content
Location Nephrology (Carlton). 2016 Mar;21(3):170-7
Date 2016-03-26
Authors Professor Luis Vitetta
Link https://www.ncbi.nlm.nih.gov/pubmed/26239363
Uremia and Chronic Kidney Disease: The Role of Probiotics / Prebiotics
Title Content
Location Molecular Nutrition and Food Research 2013; 57(5): 824-832
Date 2013-05-01
Authors Professor Luis Vitetta
Link http://www.ncbi.nlm.nih.gov/pubmed/23450842
The Gastrointestinal Microbiome and Musculoskeletal Diseases: A Beneficial Role for Probiotics and Prebiotics
Title Content
Location Pathogens 2013; 2(4): 606-626
Date 2013-11-14
Authors Professor Luis Vitetta , Dr. Samantha Coulson , Anthony W Linnane
Link http://www.mdpi.com/2076-0817/2/4/606
The Gastrointestinal Microbiota and Multi-Strain Probiotic Therapy: In Children and Adolescent Obesity
Title Content
Location Advances in Integrative Medicine 2013; 1(1): 2-8
Date 2014-01-01
Authors Professor Luis Vitetta , Talia Palacios , Dr. Samantha Coulson
Link http://www.aimedjournal.com/article/S2212-9626(13)00016-3/abstract
From the Gastrointestinal Tract (GIT) to the Kidneys: Live Bacterial Cultures (Probiotics) Mediating Reductions of Uremic Toxin Levels via Free Radical Signaling
Title Content
Location Toxins 2013; 5(11): 2042-2057
Date 2013-11-07
Authors Professor Luis Vitetta , Anthony W Linnane
Link http://www.mdpi.com/2072-6651/5/11/2042
The Pharmacobiotic Potential of the Gastrointestinal Tract Micro-Biometabolome-Probiotic Connect: A Brief Commentary
Title Content
Location Drug Development Research 2013; 74(6): 353-359
Date 2013-07-22
Authors Professor Luis Vitetta , Holiie Alford
Link http://onlinelibrary.wiley.com/doi/10.1002/ddr.21091/abstract
Live Probiotic Cultures and the Gastrointestinal Tract: Symbiotic Preservation of Tolerance Whilst Attenuating Pathogenicity
Title Content
Location Front. Cell. Infect. Microbiol., 15 October 2014 | https://doi.org/10.3389/fcimb.2014.00143
Date 2014-10-15
Authors Professor Luis Vitetta , Dr. Sean Hall , Anthony W Linnane
Link http://journal.frontiersin.org/Journal/10.3389/fcimb.2014.00143/abstract
Effects of probiotics supplementation on gastrointestinal permeability, inflammation and exercise performance in the heat
Title Content
Location European Journal of Applied Physiology 2014; 114(1):93-103
Date 2014-01-01
Authors Professor Luis Vitetta
Link http://www.ncbi.nlm.nih.gov/pubmed/24150782
Endocellular Regulation of Free Radicals and Hydrogen Peroxide: Key Determinants of the Inflammatory Response
Title Content
Location Inflammopharmacology 2014; 22(2):69-72
Date 2014-04-22
Authors Professor Luis Vitetta , Anthony W Linnane
Link http://www.ncbi.nlm.nih.gov/pubmed/24562527
The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures
Title Content
Location Pharmaceuticals 2014; 7(9): 954-89
Date 2014-09-19
Authors Professor Luis Vitetta , Rachel Manuel , Joyce Zhou , Anthony W Linnane , Dr. Sean Hall , Dr. Samantha Coulson
Link http://www.ncbi.nlm.nih.gov/pubmed/25244509
Metabolic Interactions in the Gastrointestinal Tract (GIT): Host, Commensal, Probiotics, and Bacteriophage Influences
Title Content
Location Microorganisms 2015;3(4):913-932
Date 2015-12-17
Authors Professor Luis Vitetta , Dr. Sean Hall , Dr. Samantha Coulson
Link http://www.mdpi.com/2076-2607/3/4/913
Lactobacillus acidophilus Restores Functionality in Uremic Macrophages: Plausible or Lacking Evidence?
Title Content
Location Digestive Diseases and Sciences. 2016;61(6):1417-1419.
Date 2016-06-01
Authors Professor Luis Vitetta
Link http://www.ncbi.nlm.nih.gov/pubmed/26888768
Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease
Title Content
Location Therapeutic Advances in Gastroenterology 2016;9(4):463-472.
Date 2016-05-01
Authors Professor Luis Vitetta
Link http://tag.sagepub.com/content/early/2016/04/28/1756283X16645055.abstract
Modulating the Gut Micro-Environment in the Treatment of Intestinal Parasites.
Title Content
Location Journal of Clinical Medicine 2016;5(11):pii: E102.
Date 2016-11-16
Authors Professor Luis Vitetta , Emma Saltzman , Tessa Nikov , Isabella Ibrahim , Dr. Sean Hall
Link https://www.ncbi.nlm.nih.gov/pubmed/27854317
Gastrointestinal Tract Commensal Bacteria and Probiotics: Influence on End-Organ Physiology.
Title Content
Location Progress in Drug Research Novel Natural Products: Therapeutic Effects in Pain, Arthritis And Gastro-Intestinal Diseases [Editors: K D Rainsford, M C Powanda and M W Whitehouse] Publisher: Springer Basel AG. 2015. ISBN 9783-0348-0926-9.
Date 2015-01-01
Authors Professor Luis Vitetta , Holiie Alford , Talia Palacios , Dr. Samantha Coulson
Link https://www.researchgate.net/publication/280826771_Gastrointestinal_Tract_Commensal_Bacteria_and_Probiotics_Influence_on_End-Organ_Physiology
Gut Microbiota and Metabolic Syndrome: How a Multi-Strain Probiotic may Influence Biomarkers in Obese Adolescents.
Title Content
Location 3rd International Conference on the Science of Nutrition in Medicine and Healthcare. May 3-5, 2013. Sydney Australia
Date 2013-05-03
Authors Professor Luis Vitetta , Dr. Samantha Coulson , Talia Palacios
Link https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=2ahUKEwj5lsDs3IzpAhWT6nMBHdXfDtIQFjABegQIAxAB&url=https%3A%2F%2Fwww.anhinternational.org%2Fevent%2F3rd-international-conference-on-the-science-of-nutrition-in-medicine-and-healthcare%2F&usg=AOvVaw1xrZQGoqty0VIKDIBtUjFL
The Effect Of Microbiota-Based Interventions And Metformin In Metabolic And Inflammatory Biomarkers In Adults With Type 2 Diabetes Mellitus (T2DM).
Title Content
Location 4th International Conference on the Science of Nutrition in Medicine and Healthcare. 2014 May 3-5, 2014. Gold Coast, Australia
Date 2014-05-03
Authors Professor Luis Vitetta , Dr. Samantha Coulson , Talia Palacios
Neonatal and Infant Development: Influence of Bacteria.
Title Content
Location National Institute of Integrative Medicine. 2nd Annual Symposium. November 28-29, 2015. Melbourne, Australia.
Date 2015-11-28
Authors Dr. Samantha Coulson
Link https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwij8-3M3orpAhXabSsKHQoBCBAQFjAAegQIAxAB&url=https%3A%2F%2Fwww.niim.com.au%2Fsites%2Fdefault%2Ffiles%2FNIIM-2nd-Annual-Symposium-digital.pdf&usg=AOvVaw3dp-AxlQajqMi8DmvsxE0I
High Fat Diet, Probiotics and Non–Alcoholic Fatty Liver Disease
Title Content
Location General Practice Conference and Exhibition [Sydney, Melbourne] 2015
Date 2015-01-01
Authors Professor Luis Vitetta , Dr. Samantha Coulson
Live Probiotic Cultures and the Gastrointestinal Tract – Improving More Than Just GI Health
Title Content
Location General Practice Conference and Exhibition [Sydney, Melbourne] 2015
Date 2015-01-01
Authors Professor Luis Vitetta , Dr. Samantha Coulson
Invitation to speak at Opening Ceremony and Keynote Forum session: The Microbiome - A Universe of Therapeutic Potential.
Title Content
Location BIT’s 14th Annual Congress of IDDST June 16-18, 2016. South Korea
Date 2016-06-16
Authors Dr. Sean Hall
Metabolic Disorders: Instruction by the Gut Microbiome
Title Content
Location General Practitioner Conference and Exhibition [Sydney] 2016
Date 2016-01-01
Authors Professor Luis Vitetta , Dr. Samantha Coulson
Mitigating the symptoms of chronic diseases through the administration of probiotics.
Title Content
Location Functional Food Center 22nd International Conference for Chronic Diseases Harvard Medical School, Boston USA. 23rd September 2017
Date 2017-09-23
Authors Professor Luis Vitetta
Cancer Treatments, the Intestinal Microbiome and Probiotics.
Title Content
Location IPA World Congress Asia Probiota. Singapore. 11-13 October 2017
Date 2017-10-11
Authors Professor Luis Vitetta
The intestinal microbiome, chemotherapy and adjuvant treatments with probiotics.
Title Content
Location Asia-Pacific Journal of Clinical Oncology [Clinical Oncological Society of Australia] November 13-15; 2017, Sydney, Australia.
Date 2017-11-13
Authors Professor Luis Vitetta , Michael Thomsen
Intestinal Microbiome and Cancer Treatments/ Gut health Panel.
Title Content
Location NIIM Integrative Medicine: The art & science, 4th Annual Symposium 2017 Richmond, Melbourne
Date 2017-11-24
Authors Professor Luis Vitetta
Is co-prescribing a multi-strain probiotic the simple solution for treating and preventing Proton Pump Inhibitor (PPIs) induced Clostridium difficile Associated Diarrhoea (CDAD) while maintaining evidence based pharmacotherapy?
The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized controlled trial
Title Content
Location Trials. 2017 Jan 9;18(1):7
Date 2017-01-01
Authors Professor Luis Vitetta , Talia Palacios , Dr. Samantha Coulson
Link https://www.ncbi.nlm.nih.gov/pubmed/28069054
Intestinal microbiome shifts, dysbiosis, inflammation and non-alcoholic fatty liver disease
Title Content
Location Frontiers in Microbiology – section Microbial Immunology. 2018
Date 2018-01-30
Authors Emma Saltzman , Talia Palacios , Michael Thomsen , Professor Luis Vitetta
Link https://pubmed.ncbi.nlm.nih.gov/29441049/
Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis
Title Content
Location Integrative Cancer Therapies. 2018 Dec; 17(4): 1027–1047.
Date 2018-12-01
Authors Michael Thomsen , Professor Luis Vitetta
Link https://www.ncbi.nlm.nih.gov/pubmed/30136590
The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments
Title Content
Location Beneficial Microbes. 2018 Dec 7;9(6):899-916. doi: 10.3920/BM2017.0172
Date 2018-12-01
Authors Michael Thomsen , Professor Stephen Clarke , Professor Luis Vitetta
Link https://www.ncbi.nlm.nih.gov/pubmed/30232908
Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics
Title Content
Location J Cell Biochem. 2019 Mar;120(3):2713-2720. doi: 10.1002/jcb.27635. Epub 2018 Nov 15.PMID: 30443932
Date 2019-03-01
Authors Dr. Jiezhong Chen , Michael Thomsen , Professor Luis Vitetta
Link https://pubmed.ncbi.nlm.nih.gov/30443932/?from_term=jiezhong+chen&from_sort=pubdate&from_pos=10

Related Clinical Trials


MultiBiotic™
Title Content
Name MultiBiotic™
Type Mucositis
About

Phase 1 safety and tolerability study evaluating whether probiotic supplementation prevents chemotherapy-induced diarrhoea and other intestinal adverse effects in cancer patients.

Chemotherapy and radiotherapy are associated with widespread mucositis manifesting as pain, inflammation, dysphagia, diarrhoea, weight loss, rectal bleeding and infection. 

Mucositis is a major dose-limiting side effect of chemotherapy and limits nutritional intake and oral function, resulting in weight loss and malnutrition. Chemotherapy is also detrimental to the friendly bacteria of the gastrointestinal tract causing localized infection and blood infection and almost always leads to immune suppression (neutropenia).

The prevention of cancer therapy-induced mucositis through probiotics has been investigated in randomised clinical trials with some promising results including a significantly decreased incidence of diarrhoea and infectious complications. 

A recent systemic review and meta-analysis of probiotics for prevention of chemoradiotherapy-induced diarrhoea in people with abdominal and pelvic cancers found that probiotics were generally beneficial in treatment-induced diarrhoea.

Formulation

Multibiotic™ is a multi-species probiotic formulation consisting of lactobacilli and bifidobacteria predominately, that has been laboratory and clinically evaluated to improve the stability of the intestinal microbial cohort, especially during and after the administration of pharmaceutical medicines such as antibiotics, proton pump inhibitors, analgesic medications and other.

Date started 2017-12-07
Date of HREC approval 2017-11-25
HREC name National Institute of Integrative Medicine HREC
HREC approval ID 0043E_2017
ANZCTR ACTRN12618000927224
ANZCTR URL Link http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375186&isReview=true
Study Site Northern Cancer Institute, 38 Pacific Hwy, St Leonards NSW 2065
Status Recruiting
Progression FIH Safety & Efficacy - Recruiting
Brand VMS
Product Family MultiBiotic
Partner Northern Cancer Institute
Publications and presentations The Effect Of Microbiota-Based Interventions And Metformin In Metabolic And Inflammatory Biomarkers In Adults With Type 2 Diabetes Mellitus (T2DM). , Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease , Invitation to speak at Opening Ceremony and Keynote Forum session: The Microbiome - A Universe of Therapeutic Potential. , Metabolic Disorders: Instruction by the Gut Microbiome , Cancer Treatments, the Intestinal Microbiome and Probiotics. , The intestinal microbiome, chemotherapy and adjuvant treatments with probiotics. , Intestinal Microbiome and Cancer Treatments/ Gut health Panel. , Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis , The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments , Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics

A4 Product Flyers